Dapagliflozina shows the reduction of heart risk in diabetes patients

Forxiga administration (Dapagliflozine) has demonstrated the reduction of cardiac events in patients with type 2 diabetes, as shown in Declare's results, phase 3 testing promoted by Astrazeneca.The essay has been carried out by the Timi Study Group, in Boston, in collaboration with the Hassah Hebrew University Medical Center, of Jerusalem.

The data, presented within the framework of the American Heart Association Congress 2018, held in Chicago, are of special relevance since the sample selected for this study is very broad and heterogeneous: a total of 17,160 patients from 33 different countries have participated in the studyRegardless of whether they had suffered a cardiovascular event previously or not, which allows you to approximate the results of the work for the effects that the drug would have, an SGLT-2 inhibitor, globally.

The results of the study, to general features, have shown that there has been a reduction of several of the complications derived from type 2 diabetes both at the cardiological and nephrological level.

Hospitalization reduction

The essay, carried out for more than five years, has demonstrated several positive effects of this drug.Among them include a reduction in the hospitalization of patients with type 2 diabetes due to heart failure, as well as mortality from cardiovascular events.

There has also been a reduction in the incidence of major cardiovascular events (MACpathology.Even so, experts affect the need to take into account other factors that influence cardiovascular diseases, such as weight control or abandonment of harmful habits such as smoking, so that the medicine is really effective.

Security profile

The study also certifies that the drug meets the safety criteria in amputations, bladder cancer or Fournier gangrene.What has been observed is a slight increase in diabetic ketoacidosis and genital infections.

Once the results were presented, experts attending the conference were favorable to prescribe the medicine to avoid complications (86 percent), compared to 14 percent who voted against their prescription.